Table 12:

Intervention and Comparator Evaluated in Primary Economic Model: Reference Case Analysis

Intervention	Comparator	Population	Outcomes
Multi-gene (i.e., 2 or more genes) pharmacogenomic tests that include a clinical decision-support toola to guide depression medication selection or dose adjustment (e.g., GeneSight, Myriad)	TAU: Antidepressant therapy according to the current CANMAT guidelines6 without use of multi-gene pharmacogenomic testing	Adults with major depression who had inadequate response to at least one medication	Direct medical costs QALYs

Abbreviations: CANMAT, Canadian Network for Mood and Anxiety Treatments; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; TAU, treatment as usual.

^aDecision-support tools are defined as tools that guide choice of medication or dosage recommendations.